Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motixafortide - Biokine Therapeutics/BioLineRx

Next Previous
Drug Profile

Motixafortide - Biokine Therapeutics/BioLineRx

Alternative Names: 4F-Benzoyl-TN14003; APHEXDA; BKT-140; BL-8040; GFH-168; TF-14016; TN-14003

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyoto University
  • Developer Biokine Therapeutics; BioLineRx; Genentech; Merck & Co
  • Class Antianaemics; Antineoplastics; Cyclic peptides; Peptides
  • Mechanism of Action Apoptosis stimulants; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Stem cell mobilisation; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stem cell mobilisation
  • Phase II Acute myeloid leukaemia; Adenocarcinoma; Aplastic anaemia; Myelodysplastic syndromes; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Gastric cancer
  • No development reported Adult respiratory distress syndrome
  • Discontinued Chronic myeloid leukaemia; Thrombocytopenia

Most Recent Events

  • 06 Dec 2025 Adverse events and pharmacodynamics data from a phase-I trial in Stem cell mobilisation (multiple myeloma) presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 06 Dec 2025 Updated adverse events and pharmacodynamics data from a phase-I trial in Stem cell mobilisation (sickle cell disease) presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 24 Jun 2025 Biogen in collaboration with Washington University School of Medicine completes Phase-I clinical trials in Stem cell mobilisation (Combination therapy, Monotherapy) in USA (SC) (NCT05618301)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top